Clinical trial NCT03635996: Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302
Official title: Multi-Centre, Open-Label, Safety Study of Etripamil Nasal Spray in Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The NODE-302 Trial (Extension of NODE-301)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Paroxysmal Supraventricular Tachycardia
Keywords: Paroxysmal supraventricular tachycardia
cardiac monitoring
atrioventricular nodal reentrant tachycardia
atrioventricular reciprocating tachycardia
calcium channel blocker
conversion rate
Lead sponsor: Milestone Pharmaceuticals Inc.
Sponsor class: OTHER
Collaborators: name: Medpace, Inc.
First posted: 2018-08-17
Enrollment: 169
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The primary objective of this study is to evaluate the safety of etripamil nasal spray (NS) 70 mg when self-administered by patients with an episode of Paroxysmal Supraventricular Tachycardia in an outpatient setting (i.e., without medical supervision).

Detailed description: The NODE-302 study is an extension of the NODE-301 efficacy study. It is a multi-centre, open label study designed to evaluate the safety of etripamil NS 70 mg when self-administered by patients for spontaneous episodes of PSVT in an outpatient setting. All patients randomized in the NODE-301 study and who meet the inclusion and exclusion criteria of the NODE-302 study are eligible for the NODE-302 study.

After each episode of PSVT, patients will have the option to continue in the NODE-302 study and manage subsequent episodes of PSVT with etripamil NS 70 mg if they do not meet any withdrawal criteria.

Each episode of PSVT will be documented by an ambulatory cardiac monitoring system (CMS) that will be placed on the chest by the patient or caregiver when symptoms begin, and will record at least 5 hours of continuous ECG.

The study will include a Qualification Visit, a Treatment Period(s) , a Follow-up Visit(s) ,a Final Study Visit and if necessary an Early Termination Visit if the patient withdraws from the study after taking etripamil NS 70 mg and had a Follow-up Visit, or the patient withdraws from the study and did not take etripamil NS 70 mg.

Eligibility criteria: Inclusion Criteria

Patients who meet all of the following criteria will be eligible to participate in the study:

1. Male or female patients at least 18 years of age;
2. Signed the NODE-302 written informed consent;
3. Previously randomized in the NODE-301 study:

   * Received the study drug to treat symptoms the patient believed were consistent with an episode of PSVT during the NODE-301 study, irrespective of the study drug efficacy; OR
   * Did not experience an episode of PSVT or did not use the study drug at the time of the NODE-301 study completion;
4. Willing and able to comply with all aspects of the study;
5. Females of childbearing potential who are sexually active must agree to use an approved highly effective form of contraception from the time of signed informed consent until 30 days after the last administration of study drug. Females of childbearing potential should have a negative urine pregnancy test result at the Qualification Visit and at the Follow-up Visit(s), and must use an approved form of contraception between the 2 visits. Approved forms of contraception include hormonal intrauterine devices and hormonal contraceptives (oral birth control pills, Depo Provera®, patch, or other injectables) together with supplementary double barrier methods, such as condoms or diaphragms with spermicidal gel or foam;

   The following categories define females who are NOT considered to be of childbearing potential:
   * Premenopausal females with 1 of the following:

     1. Documented hysterectomy,
     2. Documented bilateral salpingectomy, or
     3. Documented bilateral oophorectomy, or
   * Postmenopausal females, defined as having amenorrhea for at least 12 months without an alternative medical cause; and
6. Male patients, except those who are surgically sterile, must use an approved highly effective form of contraception during the 3 days after study drug administration.

Exclusion Criteria

Patients who meet any of the following criteria will be excluded from participation in the study, including but not limited to:

1. Evidence of new severe arrhythmia discovered since the NODE-301 Test Dose Randomization Visit, including those reported on the Cardiac Monitoring System (CMS) report of the outpatient PSVT event treated with the study drug in the NODE 301 study:

   d. Third-degree Atrioventricular (AV) block, Mobitz II second-degree AV block, or Wenckebach with bradycardia ≤40 bpm; e. Significant symptomatic sinus bradycardia heart rate (HR) ≤40 bpm or sinus pauses (≥3 seconds); f. Any significant ventricular arrhythmia (premature ventricular beats and couplets \[\>6 premature ventricular contractions per 45 seconds electrocardiogram (ECG)\] are considered significant); or g. Atrial fibrillation (event lasting longer than 30 seconds);
2. Any drug-related or procedure-related serious adverse event during the NODE-301 study;
3. Any severe adverse event (AE) in the NODE-301 study that was severe enough to preclude administration of etripamil NS 70 mg in the NODE-302 study;
4. Any new drug prescribed after the end of the patient's participation in the NODE-301 study that could lower blood pressure or decrease AV node conduction;
5. Systolic blood pressure \<90 mmHg after a 5-minute rest in sitting position at the NODE-302 Qualification Visit;
6. Any symptoms consistent with clinically severe hypotension such as presyncope, medically significant lightheadedness, syncope, nausea, or vomiting;
7. New therapy with digoxin, amiodarone, or any Class I or III antiarrhythmic drug added after the end of the patient's participation in the NODE-301 study;
8. New evidence of ventricular pre-excitation (e.g., delta waves, short PR interval, Wolff Parkinson-White syndrome) on the ECG since randomization in the NODE-301 study;
9. New symptoms of congestive heart failure defined by the New York Heart Association Class II to IV since randomization in the NODE-301 study;
10. New stroke since randomization in the NODE-301 study;
11. New evidence of a significant physical or psychiatric condition including drug abuse, which in the opinion of the Investigator, could jeopardize the safety of the patient, or impede the patient's capacity to follow the study procedures since randomization in the NODE-301 study;
12. New syncope since randomization in the NODE-301 study, especially if observed during the monitoring of the event treated in the NODE-301 study;
13. New evidence of hepatic dysfunction defined as alanine aminotransferase or aspartate aminotransferase \>3 × the upper limit of normal (ULN) or total bilirubin \>2 × ULN, unless due to Gilbert syndrome observed at the NODE-302 Qualification Visit;
14. New evidence of renal dysfunction as determined by an estimated glomerular filtration rate assessed at the NODE-302 Qualification Visit as follows:

    1. \<60 mL/min/1.73 m2 for patients \<60 years of age,
    2. \<40 mL/min/1.73 m2 for patients ≥60 and \<70 years of age, or
    3. \<35 mL/min/1.73 m2 for patients ≥70 years of age;
15. Participation in any investigational drug or device study or the use of any investigational drug or device since the Final Study Visit in the NODE-301 study.

Withdrawal Criteria

Patient participation in this clinical study may be discontinued for any of the following reasons:

* The patient withdraws consent or requests discontinuation from the study for any reason;
* The patient took the study drug in both the NODE-301 and the NODE-302 studies for symptoms not associated with an episode of PSVT;
* Occurrence of any medical condition, AE, or circumstance that exposes the patient to substantial risk and/or does not allow the patient to adhere to the requirements of the protocol;
* Requirement of a prohibited concomitant medication and/or change in the use of chronic therapies, such as concomitant beta-blockers, calcium channel blockers, and medications that can lower blood pressure;
* Patient failure to comply with protocol requirements or study-related procedures;
* Termination of the study by Milestone or a regulatory authority; or
* The patient self-administered a total of 11 doses of etripamil Nasal Spray 70 mg in the NODE-302 study.

Patients who withdraw from the study after taking etripamil Nasal Spray 70 mg and had a Follow-up Visit will be required to undergo an Early Termination Visit.

Patients who withdraw from the study and did not take etripamil Nasal Spray 70 mg will be required to undergo an Early Termination Visit.

Patients who withdraw after taking the study drug but did not have a Follow-up Visit will be required to undergo a Final Study Visit.

Primary outcomes:
measure: Time to Conversion of an Episode of PSVT to Sinus Rhythm (SR) After Study Drug Administration.
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Arizona Arrhythmia Research Center
state: Arizona
city: Little Rock
country: United States
facility: Arkansas Cardiology
state: Arkansas
city: Los Alamitos
country: United States
facility: Los Alamitos Cardiovascular
state: California
city: Littleton
country: United States
facility: South Denver Cardiology Associates, P.C
state: Colorado
city: Jacksonville
country: United States
facility: Baptist Health Ambulatory Services
state: Florida
city: Jacksonville
country: United States
facility: Mayo Clinic - Jacksonville
state: Florida
city: New Smyrna Beach
country: United States
facility: Edgewater Medical Research
state: Florida
city: Atlanta
country: United States
facility: Piedmont Heart Institute
state: Georgia
city: Columbus
country: United States
facility: Columbus Regional Research Institute
state: Georgia
city: Macon
country: United States
facility: Georgia Arrythmia Consultants&Research Institute
state: Georgia
city: West Des Moines
country: United States
facility: Iowa Heart Center
state: Iowa
city: Baltimore
country: United States
facility: MedStar Health Research Institute
state: Maryland
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Morristown
country: United States
facility: Atlantic Health System - Morristown Medical Center
state: New Jersey
city: Buffalo
country: United States
facility: Trinity Medical WNY, PC
state: New York
city: New York
country: United States
facility: Weill Cornell Medical Center
state: New York
city: Charlotte
country: United States
facility: The Presbyterian Hospital DBA Novant Health Heart and Vascular Institute
state: North Carolina
city: Springfield
country: United States
facility: Heart House Research Foundation, LLC
state: Ohio
city: Rapid City
country: United States
facility: Black Hills Cardiovascular Research
state: South Dakota
city: Houston
country: United States
facility: Baylor College of Medicine
state: Texas
city: Round Rock
country: United States
facility: Baylor Scott and White Research Institute - Round Rock
state: Texas
city: Murray
country: United States
facility: IHC Health Services Inc. DBA Intermountain Medical Center
state: Utah
city: Calgary
country: Canada
facility: Libin Cardiovascular Institute of Alberta - University of Calgary
state: Alberta
city: Edmonton
country: Canada
facility: Royal Alexandra Hospital
state: Alberta
city: Vancouver
country: Canada
facility: Vancouver General Hospital - Research Institute ; Gordon and Leslie Diamond Health Centre
state: British Columbia
city: Victoria
country: Canada
facility: Victoria Cardiac Arrhythmia Trials, Inc.
state: British Columbia
city: Winnipeg
country: Canada
facility: University of Manitoba, St Boniface General Hospital
state: Manitoba
city: Cambridge
country: Canada
facility: Cambridge Cardiac Care Centre
state: Ontario
city: Guelph
country: Canada
facility: Dawson Road Medical Centre
state: Ontario
city: Hamilton
country: Canada
facility: Hamilton Health Sciences
state: Ontario
city: Newmarket
country: Canada
facility: Partners in Advanced Cardiac Evaluation (PACE) Cardiology Clinic
state: Ontario
city: Toronto
country: Canada
facility: St. Michael's Hospital
state: Ontario
city: Montréal
country: Canada
facility: Montreal Heart Institute - Institut de Cardiologie de Montréal
state: Quebec
city: Sherbrooke
country: Canada
facility: CIUSSS de l'Estrie - CHUS ; Hôpital Fleurimont
state: Quebec
Study officials:
References: